P5.082 What Are the Costs and Benefits of Implementing Point of Care Tests For Chlamydia Trachomatis and Neisseria Gonorrhoeae in Genitourinary Medicine Clinics?

K M Turner,E Adams,J Round,S Goldenberg,J Macleod,P Horner,A Deol

doi:10.1136/sextrans-2013-051184.1126

Abstract

BackgroundTo estimate the costs and benefits of new patient pathways in genitourinary medicine (GUM) clinics that incorporate a point of care (POC) nucleic acid amplification test (NAAT) for chlamydia and...

Highlights

Positive Negative TotalAnalytical Evaluation of the GeneXpert® CT/ NG, the First Genetic Point of Care Assay For Simultaneous Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis doi:10.1136/sextrans-2013-051184.1125
New assays for molecular detection of Neisseria gonorrhoeae and Chlamydia trachomatis need to be evaluated for potential false positive and false negative results due to cross reaction with other species, and potential mutations and genetic exchanges with other closely related organisms
Our results show that majority of cases studied were due to HSV-2, HSV-1 either alone or as a mixed infection with HSV-2 is not uncommon

Summary

Positive Negative Total

Analytical Evaluation of the GeneXpert® CT/ NG, the First Genetic Point of Care Assay For Simultaneous Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis doi:10.1136/sextrans-2013-051184.1125. 1,2S N Tabrizi, 3M Unemo, 4D Golparian, 5J Twin, 6A E Limnios, 6M Lahra, 7R Guy, on behalf of TTANGO Investigators.

Introduction

Background